Charles River Laboratories International, Inc. (NYSE: CRL) announced on January 30 that it acquired SAMDI Tech, Inc. The purchase price was $50 million in cash for 80% ownership.
Based in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS for identifying binding interactions.
Charles River Laboratories is a provider of research tools and integrated support services that enable drug discovery and development, including genetically and virally defined purpose-bred lab animals. In 2021, the company reported revenue of $3.54 billion.
The combination of Charles River’s end-to-end portfolio and scientific expertise with SAMDI Tech’s MS technology and expertise in assay solutions has the potential to accelerate clients’ discovery efforts by measuring biochemical activities and identifying binding interactions for virtually any small molecule drug target. SAMDI Tech will become part of the Charles River Laboratories’ Discovery and Safety Assessment segment.
According to data captured in the LevinPro HC database, this represents the seventh contract research organization (CRO) acquisition of 2023. Throughout January 2022, there were two CRO transactions announced.
